GW Pharmaceuticals PLC- ADR (GWPH) stock is lower by 4.63% over the past week and gets a Neutral rating from InvestorsObserver's Sentiment Indicator.
What is Stock Sentiment?
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With GWPH Stock Today?
GW Pharmaceuticals PLC- ADR (GWPH) stock is down -2.39% while the S&P 500 has gained 1.21% as of 1:21 PM on Monday, Nov 2. GWPH is lower by -$2.15 from the previous closing price of $90.01 on volume of 223,041 shares. Over the past year the S&P 500 has risen 7.51% while GWPH is lower by -35.47%. GWPH lost -$1.79 per share in the over the last 12 months.
More About GW Pharmaceuticals PLC- ADR
GW Pharmaceuticals PLC is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The company's lead product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol used for the treatment of a number of rare childhood-onset epilepsy disorders. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. Geographically its presence can be seen across the region of UK, Europe, US, Canada, and others.